

Table 1: Evaluation Parameters for selecting predictors for PIP medication use in older adult patients (n=456).

Variables	No of patients (%)	No of patients with PIMs use as per Beers criteria 2019	No of patients with PIMs use as per STOPP criteria 2015	Beers criteria 2019 Odds Ratio (OR) (95% CI)	P-value	STOPP criteria 2015 Odds Ratio (OR) (95% CI)	P-value
Gender							
Male	272 (59.6)	250 (92.0)	198 (72.7)	1 (reference)		1 (reference)	
Female	184 (40.4)	168 (91.4)	138 (75.0)	0.92(0.47-1.81)	0.818	1.16 (0.75-1.78)	0.487
Age in years							
65- 70	358 (78.5)	325 (90.8)	266 (74.4)	1 (reference)		1 (reference)	
71- 75	66 (14.4)	63 (95.4)	43 (65.2)	2.13(0.63-7.16)	0.221	0.64 (0.36-1.13)	0.126
76- 80	22 (4.9)	21 (95.4)	19 (86.4)	2.13(0.27-16.36)	0.466	2.19 (0.63-7.57)	0.215
≥81	10 (2.2)	9 (90.0)	8 (80.0)	0.91 (0.11-7.43)	0.933	0.80 (0.20-3.18)	0.760
Alcohol or smoking addiction							
No addiction	404 (88.6)	371 (91.8)	289 (71.5)	1 (reference)		1 (reference)	
Smoking	18 (4.0)	16 (88.8)	14 (77.7)	0.71 (0.15-3.22)	0.659	1.39 (0.44-4.32)	0.566

Alcoholic	34 (7.4)	32 (94.1)	33 (97.0)	1.42 (0.32-6.20)	0.639	13.13 (1.77-97.14)	0.012
Rural or urban background							
Urban	256 (56.2)	228 (89.0)	178 (69.5)	1 (reference)		1 (reference)	
Rural	200 (43.8)	191 (95.6)	158 (79.0)	2.60 (1.20-5.65)	0.015	1.64 (1.07-2.53)	0.023
Number of Psychotropics used							
1	10 (2.2)	8 (80.0)	6 (60.0)	1 (reference)		1 (reference)	
2	110 (24.2)	93 (84.5)	78 (71.0)	1.36 (0.26-7.0)	0.707	1.62 (0.42-6.14)	0.474
3	186 (40.7)	171 (92.0)	137 (73.6)	2.85 (0.55-14.64)	0.210	1.86 (0.50-6.88)	0.350
≥4	150 (32.9)	147 (98.0)	115 (76.6)	12.25 (1.78-84.0)	0.011	2.19 (0.58-8.20)	0.244
Use of Antidepressant (AD) drugs							
No AD	142 (31.2)	133 (93.6)	76 (53.5)	1 (reference)		1 (reference)	
TCA	78 (17.2)	64 (82.0)	76 (97.4)	0.30 (0.12-0.75)	0.010	33 (7.80-139.59)	<0.001
SSRI	212 (46.5)	204 (96.2)	170 (80.1)	1.72 (0.64-4.58)	0.274	3.51 (2.19-5.63)	<0.001
SNRI	24 (5.1)	18 (75.0)	14 (58.3)	0.20 (0.06-0.63)	0.006	1.21 (0.50-2.91)	0.662
Benzodiazepines (BZD)							
No BZD	78 (17.2)	53 (67.9)	24 (30.7)	1 (reference)		1 (reference)	
LABZD	290 (63.6)	286 (98.6)	286 (98.6)	33.72 (11.27-	<0.001	160.87 (53.67-	<0.001

				100.85)		482.19)	
Short-acting BZD	88 (19.2)	80 (90.9)	26 (29.5)	4.71 (1.97-11.24)	<0.001	0.94 (0.48-1.83)	0.864
Antipsychotics (AP)							
No AP	224 (49.2)	187 (83.4)	183 (81.6)	1 (reference)			
Atypical	228 (50.0)	226 (99.1)	151 (66.2)	22.35 (5.31-93.99)	<0.001	0.43 (0.28-0.67)	<0.001
Conventional	4 (0.8)	3 (75.0)	2 (50.0)	0.59 (0.06-5.86)	0.655	0.22 (0.03-1.63)	0.140

P-value <0.05 were considered significant.

SSRI, Selective Serotonin Reuptake Inhibitor; SNRI, Serotonin Norepinephrine Reuptake Inhibitor

Table 2: PIMs use identified by Beers criteria and STOPP criteria

PIMs category	Number of Patients with PIMs as per Beers criteria 2019	Number of patients with PIMs as per STOPP criteria 2015
Independent of diagnosis	634	354
Drug-disease interaction	178	60
Used with caution	34	30
Clinically important drug-drug interaction	136	-
According to the kidney function	18	-